Investigating hypophosphataemia

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Glendenning, Paul ^a,b   Bell, Damon A ^a,b   Clifton Bligh, Roderick J ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; CALCIUM ION; ELECTROLYTE; FIBROBLAST GROWTH FACTOR 23; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ACUTE DISEASE; ASYMPTOMATIC DISEASE; BLOOD EXAMINATION; CANCER CHEMOTHERAPY; CHRONIC DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION TEST; LABORATORY TEST; MALNUTRITION; MEDICAL EXAMINATION; MEDICAL SPECIALIST; METABOLIC REGULATION; NOTE; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROTEIN DETERMINATION; REFEEDING SYNDROME; REFERENCE VALUE; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SYMPTOM; URINALYSIS; VITAMIN D DEFICIENCY;

BIOLOGICAL MARKERS; HUMANS; HYPOPHOSPHATEMIA; PHOSPHATES;

EID: 84901702199     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3172     Document Type: Note

References (16)

1. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM 2010;103:449-59.
2. Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007;18:1999-2003. (Pubitemid 47041063)
3. Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis 2012;60:655-61.
4. Witteveen JE, van Thiel S, Romijn JA, Hamdy MA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol 2013;168:R45-53.
5. Ra'anani P, Lahav M, Prokocimer M, Poles L, Theodor E. Life threatening hypophosphataemia in a patient with Philadelphia chromosome-positive chronic myelogenous leukaemia in acute blastic crisis. Postgrad Med J 1992;68:283-6.
6. Skipper A. Refeeding syndrome or refeeding hypophosphatemia: a systematic review of cases. Nutr Clin Pract 2012;27:34-40.
7. Civitelli R, Ziambaras K. Calcium and phosphate homeostasis: concerted interplay of new regulators. J Endocrinol Invest 2011;34(7 Suppl):3-7.
8. Glendenning P. It is time to start ordering ionized calcium more frequently: preanalytical factors can be controlled and postanalytical data justify measurement. Ann Clin Biochem 2013;50(Pt 3):191-3.
9. Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf) 2007;66:35-42. (Pubitemid 44952492)
10. Jayasena CN, Modi M, Palazzo F, De Silva A, Donaldson M, Meeran K, et al. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2013;78:838-43.
11. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev 2013;34:33-83.
12. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305-12.
13. Kim YJ, Kim MG, Jeon HJ, Ro H, Park HC, Jeong JC, et al. Clinical manifestations of hypercalcemia and hypophosphatemia after kidney transplantation. Transplant Proc 2012;44:651-6.
14. Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 1998;35(Pt 2):201-6. (Pubitemid 28127549)
15. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer 2011;18:R53-77.
16. Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 2012;23:610-8.